cite this chapter pharmacotherapy in obesity...
TRANSCRIPT
Canadian Adult Obesity Clinical Practice Guidelines 1
KEY MESSAGES FOR HEALTHCARE PROVIDERS
• Therearethreemedications indicatedforchronicobesitymanagement in Canada in addition to health behaviourchanges: liraglutide (Saxenda®) 3.0 mg, naltrexone/bu-propion (Contrave®) ina combination tablet, andorlistat(Xenical®).All threemedicationshavebeen shown tobeeffectiveinproducingweightlossgreaterthanplaceboforadurationofatleastoneyear.
• Medicationsthatarenotapprovedaspharmacotherapyforobesitymanagementshouldnotbeusedforthispurpose.
• The individual response to obesity management pharma-cotherapy is heterogeneous; the response tomedicationscandifferfrompatienttopatient.Inchoosingthemostap-propriateobesitypharmacotherapy,considermechanismofaction,safety,potentialsideeffects/tolerability,contraindica-tions,druginteractions,modeofadministrationandcost.
Pharmacotherapy in Obesity Management SueD.PedersenMDi,PriyaManjooMDii,SeanWhartonMDPharmDiii
i) C-ENDODiabetes&EndocrinologyClinicii) DepartmentofEndocrinology,UniversityofBritish
Columbiaiii) DepartmentofMedicine,McMasterUniversity
Cite this Chapter
PedersenSD,ManjooP,WhartonS.CanadianAdultObesityClinicalPracticeGuidelines:PharmacotherapyinObesityManagement.Availablefrom: https://obesitycanada.ca/guidelines/pharmacotherapy. Accessed [date].
Update History
Version1,August4,2020.AdultObesityClinicalPracticeGuidelinesarealivingdocument,withonlythelatestchapterspostedatobesitycanada.ca/guidelines.
RECOMMENDATIONS
1.PharmacotherapyforweightlosscanbeusedforindividualswithBMI≥30kg/m2orBMI≥27kg/m2withadiposity-relatedcomplications,inconjunctionwithmedicalnutritiontherapy,physical activity and psychological interventions (liraglutide3.0mg[Level2a,GradeB)],1–3naltrexone/bupropioncombi-nation[Level2a,GradeB],4orlistat[Level2a,GradeB]).5
2.Pharmacotherapy may be used to maintain weight lossthathasbeenachievedbyhealthbehaviourchanges,andto prevent weight regain (liraglutide 3.0 mg or orlistat)(Level2a,GradeB).6
3.Forpeoplelivingwithtype2diabetesandaBMI≥27kg/m2, pharmacotherapy can be used in conjunction withhealthbehaviourchangesforweightlossandimprovementinglycemiccontrol:liraglutide3.0mg(Level1a,GradeA);7 naltrexone/bupropion combination (Level 2a; Grade B),8
orlistat(Level2a,GradeB).9
4.We recommend pharmacotherapy in conjunction withhealthbehaviourchangesforpeoplelivingwithprediabetesandoverweightorobesity(BMI>27kg/m2)todelayorpre-venttype2diabetes.(Liraglutide3.0mg(Level2a,GradeB);2,orlistat(Level2a,GradeB).10
5.We do not suggest the use of prescription or over-the-counter (OTC)medicationsother than thoseapproved forweightmanagement(Level4,GradeD,Consensus).
6.For people livingwith overweight or obesitywho requirepharmacotherapy forotherhealth conditions,we suggestchoosing drugs that are not associatedwithweight gain(Level4,GradeD,Consensus).
Canadian Adult Obesity Clinical Practice Guidelines 2
Introduction
Modestandsustainedweightloss(5%–10%)isassociatedwithimprovementsincomorbiditiesassociatedwithobesity.11–13Healthbehaviourmodificationsarethecornerstoneofobesitymanage-ment;however,healthbehaviourchangesaloneareoftennotsuf-ficientforachievingobesitymanagementgoals.Healthbehaviourmodificationgenerallyachievesonlya3%–5%weightloss,whichismostoftennotsustainedoverthelongterm(seethechapterEffective Psychological and Behavioural Interventions inObesityManagement).Pharmacotherapyforobesityshouldbeconsideredtodecreaseweightandimprovemetabolicand/orhealthparam-eterswhenhealthbehaviourchangealonehasbeenineffective,insufficientorwithoutsustainedbenefit.
ThischapterprovidesareviewoftheliteraturepertainingtotheefficacyoftheobesitymedicationscurrentlyapprovedbyHealthCanada. It is intended to informprimary carepractitioners andspecialistsontheappropriateuseofobesitypharmacotherapy.
HealthCanadahasestablishedthefollowingcriteriathatmustbesatisfied for a pharmacotherapeutic agent to receive regulatoryapprovalforchronicobesitymanagement:
1.Theagentmustbestudiedinclinicaltrialsofatleastoneyearinduration.
2.Theagentmustinduceaplacebo-adjustedmeanweightlossof≥5%ormustdemonstratea≥5%weightlossinatleast35%ofpatients,withthisproportionbeingmorethandoublethatinplacebo.
3.Theagentshoulddemonstrateanimprovementinobesity-relatedcomorbidities.
PharmacotherapyisindicatedforchronicobesitymanagementinCanadaforindividualswithabodymassindex(BMI)≥30kg/m2,or≥27kg/m2withcomorbiditiesassociatedwithexcessbodyfat(e.g.type2diabetes[T2DM],hypertension,dyslipidemia).
TherearethreemedicationsapprovedforobesitymanagementinCanada: orlistat, liraglutide 3.0mg and naltrexone/bupropion. It
isrecognizedthatothermedications,availableinCanadabutnotapproved forobesitymanagement,areusedoff-label forobesitymanagement.Asaresult,ourliteraturesearchemployedanopenstrategy to capture all pharmacotherapy agents that have beenstudiedforobesitymanagement.However,withtheexceptionofmetformin for prevention of antipsychotic-induced weight gain(see: TheRoleofMentalHealth inObesityManagement for themetforminrecommendation),wediscouragehealthcareprovidersfromusingagentssolelyforchronicobesitymanagementiftheydonothave regulatoryapproval for this indication.Non-prescriptiontreatments/supplementsarereviewedseparatelyintheCommercialProductsandProgramsforObesityManagementchapter.
Thischapterwilladdressclinicalquestionspertainingtotheeffi-cacyofpharmacotherapy inpeoplewithoverweightorobesity.Itwillalsosummarizeevidenceforpharmacotherapyforobesityamongpersonswithselectedcomorbidities,includingT2DM,pre-diabetes,hepaticsteatosis,polycysticovarysyndrome,obstructivesleep apnea and osteoarthritis. Randomized controlled trials ormeta-analysesofatleastsixmonthsdurationwereincludedintheliteraturereview.
Considerations in the use of pharmacotherapyfor obesity management
Thereareseveralfactorstobetakenintoconsiderationindeter-mining theappropriate choiceofpharmacotherapy forpatientswithoverweightorobesity.Theetiologyofobesityiscomplexandheterogeneous.Psychosocial,emotionalandhedoniccontributorsofobesityshouldbediagnosedandmanagedwherepossible.Themechanismofaction,adversesideeffects,safety,andtolerabilityofeachagentmustbeconsideredinthecontextofeachpatient’scomorbiditiesandexistingmedications.Thecostofmedicationsaswellasthemode(oralversussubcutaneous)andfrequencyofadministrationcanbeabarriertopatientadherenceandshouldbediscussed. It is important toassess concomitantmedicationsthatapatientistakingaspossiblecontributorstoweightgainandtoconsideralternativeswhereappropriate.
Ifclinicallysignificantweightlossisnotachievedwithpharmaco-therapy,otherfactorscontributingtoperceivedpharmacotherapyfailureshouldbeassessed,includinginappropriatedosingorad-
KEY MESSAGES FOR PEOPLE LIVING WITH OBESITY
• Obesitymedicationcanhelpyouinyourobesitymanage-mentjourneywhenhealthbehaviourchangesalonehavenotbeeneffectiveorsustainable.
• There are threemedications approved for long-termobesitymanagement in Canada: liraglutide 3.0 mg (Saxenda®),naltrexone/bupropioninacombinationtablet(Contrave®) andorlistat(Xenical®).Thesemedicationscanhelpyoutoachieveandmaintaina5%–10%weightlossandimprove
healthcomplicationsassociatedwithexcessweight.Thesemedications are approved by Health Canada and havebeenproveninrobustclinicaltrialstobeeffectiveforobesitymanagement.
• Medications thatarenotapproved forobesity treatmentmaynotbesafeoreffectiveforobesitymanagementandshouldbeavoided.
Canadian Adult Obesity Clinical Practice Guidelines 3
herence, barriers to health behaviour change, andpsychosocialormedicalissues.Itshouldalsoberecognizedthatthereiscon-siderableheterogeneityintheresponsetopharmacotherapywithanypharmacotherapeuticagent.Considerationshouldbegivento trying another obesity medication or obesity managementtherapy if clinically significant obesitymanagement success hasnotbeenachievedafterthreemonthsonfull/maximumtolerateddoseandnootherevidentetiologiesof the lackof successareapparent.Currently,wehavenoabilitytopredictwhichmedica-tionwillbenefitapatientmost.Withtheevolutionofprecisionmedicine,includinghormonalandgeneticprofiling,itmayinthefuturebecomepossible topredictwhichpharmacotherapymaybenefitanindividualpatientthemost.
Regulatoryagenciesrecommenddiscontinuingpharmacotherapyforobesity ifweight lossof≥5%hasnotbeenachievedafterthreemonths on therapeutic dose. However, pharmacotherapycanalsobeused tomaintainweight lossachievedwithapriorhealthbehaviourchangeoraverylowenergydiet.3,6
Obesitymedicationsareintendedaspartofalong-termtreatmentstrategy. Clinical trials for obesity pharmacotherapy consistentlydemonstrateregainofweightwhenactivetreatmentisstopped.2,14
Theuseofobesitypharmacotherapyisnotrecommendedinpreg-nantorbreastfeedingwomen,orinwomenwhoaretryingtocon-ceive. There is no data available to informon the timing of thediscontinuationofobesitypharmacotherapypriortoconception.
Mechanism and efficacy of approved pharmacotherapy for obesity management
Orlistat
Orlistat,a semisyntheticderivativeof lipstatin,wasapprovedaspharmacotherapy for obesity management in Canada in 1999(seeTable1). It is apotentand selective inhibitorofpancreaticlipase, thereby inhibiting thebreakdownofdietary triglyceridesintoabsorbablefreefattyacids.Asaresultofthis,approximately30%ofingestedtriglyceridesareexcreted,primarilyinthefeces,creatingacaloricdeficit.15
Todate,orlistatistheonlyavailableobesitymedicationthatdoesnotspecificallytargetappetiteorsatietymechanisms.
Orlistatatadoseof120mgthreetimesdaily(takenduringoruptoonehouraftermeals)isapprovedbyHealthCanadaforweightreductionorreducingtheriskofweightregainafterpriorweightlossinpatientswithaBMI≥30kg/m2,orBMI≥27kg/m2inthepresenceofcomorbidities(e.g.hypertension,T2DM,dyslipidemia,excessvisceralfat).16
Asystematicreviewandmeta-analysisofrandomizedcontrolledtrialsoforlistat120mgthreetimesadayreportedameanplacebosubtractedweightlossof-2.9%atoneyear.5Additionally,54%and 26% of patients achieved ≥ 5% and ≥ 10%weight loss,
respectively,comparedto33%and14%forplacebo.5Orlistathasbeenshowntobeeffectiveinmaintainingweightlossafteraverylowenergydietforeightweeks,withlessweightregainintheorli-statarmcomparedtoplacebooverthreeyears(4.6kgvs.7.0kg).6
Orlistattherapyisassociatedwithsignificantadversegastrointesti-naleffects,includingoilyspottingandstool,flatuswithdischarge,fecal urgency and increased defecation.5 These adverse effectsmaycausepatientswhodonotlowertheirdietaryfatintaketodiscontinuetherapy.Along-termanalysisofobesitymedicationsinCanadademonstratedsix-month,oneyearandtwo-yearper-sistence ratesof18%,6%and2%withorlistat, respectively.17 Orlistattherapymayinterferewiththeabsorptionoffat-solublevitamins(A,D,EandK),andpatientsshouldthusbecounselledtotakeamultivitaminat least twohoursbeforeorafter takingorlistat.5,16Orlistatiscontraindicatedinpatientswithchronicmal-absorptionsyndromeorcholestasis.Somepatientsmaydevelopincreasedlevelsofurinaryoxalateonorlistat;casesofoxalatene-phropathywithrenalfailurehavebeenreported.18Therehavealsobeenrarecasesofsevereliverinjuryoracuteliverfailure.19
AsorlistatmayinterferewithvitaminKabsorption,internationalnormalized ratioshouldbemonitoredcloselywhenoralantico-agulants are co-administered. Orlistatmay affect absorption oflevothyroxineand/oriodinesalts;patientsonlevothyroxineshouldbemonitoredforchangesinthyroidfunction.Areductioninplas-macyclosporinelevelshasbeenobservedwhenorlistatisco-ad-ministered;thus,itisrecommendedtomonitorcyclosporinelevelsmorefrequently.Orlistatmayaffectabsorptionofanticonvulsants,sopatientsonanticonvulsantsshouldbemonitoredforpossiblechangesinthefrequencyand/orseverityofseizure.16
Theminimalweightlosswithorlistataboveplaceboaswell,asitsfrequentgastrointestinalsideeffects, limit itsuseastherapyforobesitymanagement.
Liraglutide
Liraglutide is a daily, subcutaneously administered, human glu-cagon-like peptide 1 (GLP-1) analog that acts centrally on thepro-opiomelanocortin(POMC)/CARTneuronstoimprovesatiationandsatietyandreducehunger,withatransienteffecttodecreasegastricemptying.24,25
Liraglutide increases insulin release and suppresses glucagonduringtimesofglucoseelevation.LiraglutideisapprovedinCan-adaforthemanagementofT2DMatadoseof1.2mgor1.8mgdaily,withnearmaximaltherapeuticefficacyforA1Cloweringatthe1.8mgdose.LiraglutidewasapprovedinCanadain2015forchronicobesitymanagementatadoseof3.0mgdaily,inpeoplewithorwithouttype2diabetes.Therecommendedstartingdoseof liraglutide is 0.6mgdaily,with up-titration by 0.6mg eachweekuntilthe3.0mgtargetdoseisachieved.
Amongpeoplewithnormoglycemiaorprediabetes,liraglutide3.0mgwithhealthbehaviourmodificationresultedinan8.0%weightlossatoneyear,comparedto2.6%onplacebo(healthbehaviour
Canadian Adult Obesity Clinical Practice Guidelines 4
Table 1. Pharmacotherapy for Obesity*
Naltrexone/Bupropion LiraglutideOrlistat
Modeofadministration
Dose/frequency
Effecton%weightlossat1year,placebosubtracted
Effectonweightoverlongerterm,placebosubtracted
%ofpatientsachieving≥5%weightlossat1year
%ofpatientsachieving≥10%weightlossat1year
Effectonmaintenanceofpreviousweightloss
Effectonprediabetes
EffectonBPat1year, placebosubtracted
Effectonlipidsat1year,placebosubtracted
EffectonHRat1year,placebosubtracted
EffectonA1Cinpatientswithdia-betesat1year,placebosubtracted
EffectonNASH
EffectonPCOS
EffectonOA
EffectonOSA
Cost
Contraindications
Commonsideeffects
Raresideeffects
Druginteractions
Oral
120mgTID
-2.9%5
-2.8kgat4years10
54%(vs33%inplacebo)5
26%(vs14%inplacebo)5
2.4kglessweightregainvs placeboover3years6
37.3%reductioninriskof developingT2DMover4years10
-1.9mmHgSBP-1.5mmHgDBP20
-0.27mmol/Ltotalchol-0.21mmol/LLDL-0.02mmol/LHDL-0.00mmol/LTG20
Nochange
-0.4%9
Noimprovement
Notstudied
Notstudied
Notstudied
$$
•Cholestasis•Chronicmalabsorptionsyndrome16 •Pregnancy
Loose,oilystools,flatus
•Liverfailure•Nephrolithiasis•Acutekidneyinjury
•Fat-solublevitamins•Levothyroxine•Cyclosporine•Oralanticoagulants anticonvulsants16
Subcutaneous
3.0mgdaily
-5.4%1
-4.2%at3years2
63.2%(vs27.1%inplacebo)1
33.1%(vs10.6%inplacebo)1
-6.0%additionalplacebo-subtractedweightlossat1year3
79%reductioninriskofdevelopingT2DMover3years2
-2.8mmHgSBP-0.9mmHgDBP1
-2.3%totalchol-2.4%LDL+1.9%HDL-3.9%nonHDL-9.3%TG1
+2.4BPM1
-1.0%7
Improvement21
-5.2kgplacebosubtractedweightlossat6mo;nodataonmenstrualcyclicity22
Notstudied
ReducesAHIby6/hr23
$$$$
•Pasthistoryofpancreatitis•Personalorfamilyhistoryof medullarythyroidcancer
•PersonalhistoryofMEN2 syndrome
•Pregnancy
Nausea,constipation,diarrhea,vomiting
PancreatitisCholelithiasis
Mayaffectabsorptionofmedi-cationsduetoslowingofgastricemptying
Oral
16/180mgBID
-4.8%4
Notstudied
48%(vs16%inplacebo)4
25%(vs7%inplacebo)4
Notstudied
Notstudied
+1.8mmHgsBP+0.9mmHgdBP4
-1.5%LDL+7.2%HDL-9.6%TG4
+1.1BPM4
-0.5%8
Notstudied
Notstudied
Notstudied
Notstudied
$$$
•Uncontrolledhypertension•Anyopioiduse•Historyof,orriskfactorsfor,seizure•Abruptdiscontinuationofalcohol•Concomitantadministrationofmonoamineoxidaseinhibitors(MAOI)
•Severehepaticimpairment•End-stagerenalfailure•Pregnancy
Nausea,constipation,headache,drymouth,dizziness,diarrhea
•Seizure•Worseningofdepression
Yes:Seechaptertext
Canadian Adult Obesity Clinical Practice Guidelines 5
modificationalone).1 Intermsofcategoricalweightloss,63.2%ofpatientsonliraglutidelost≥5%bodyweightatoneyear,com-paredwith27.1%ofpatientsintheplacebogroup;133.1%and10.6%ofparticipantslostmorethan10%oftheirbodyweightonliraglutide3.0mgandplacebo,respectively.Patientswithpre-diabeteswerefollowedtothreeyears,withsustainedweightlossof-6.1%intheliraglutidegroupvs.-1.9%inplacebo.2
Followinga-6.0%weightlosswithalow-caloriediet,liraglutide3.0mgplus health behaviour counselling reducedweight by afurther -6.2% at one year comparedwith -0.2% in the place-bo group (ongoing health behaviour counselling alone). Morepatientson liraglutide3.0mgwereable tomaintain the≥5%run-inweightloss(81.4%)comparedwiththosereceivingplace-bo(48.9%).Fewerpatientsonliraglutide3.0mgregained≥5%bodyweight(1.9%)comparedtoplacebo(17.5%).3
Themost common side effect of liraglutide is nauseadue to atransient decrease in gastric emptying. Patientsmay also expe-rience constipation, diarrhea, heartburn and/or vomiting.Moregradual titration can helpmitigate gastrointestinal side effects,shouldtheseoccur.Liraglutideuseisassociatedwitha1.4%high-erriskofgallstonescomparedtoplacebo.26
Thereisasmallincreasedriskofpancreatitiscomparedtoplacebo,withthemajorityofthesecasesseeninassociationwithgallbladderdisease.2Liraglutideiscontraindicatedinpatientswithapersonalorfamilyhistoryofmedullarythyroidcancerorapersonalhistoryofmultipleendocrineneoplasiatype2becauseofanincreasedriskofmedullarythyroidcancerseeninrodentstudies.Therehavebeennocasesofmedullarythyroidcancer inhumanstudiesof liraglu-tide.Liraglutidedelaysgastricemptying,whichmayimpactabsorp-tionofconcomitantlyadministeredoralmedications.
Naltrexone/Bupropion
Naltrexone hydrochloride/bupropion hydrochloride is a combina-tionof twomedications.Naltrexone isanopioid receptorantag-onistthathasbeenusedfordecadesforthetreatmentofalcoholandopioiddependence.Bupropionisawidelyusedantidepressantthat inhibits the reuptakeof dopamine andnorepinephrine. Thenaltrexone/bupropionsustainedreleaseformulationwasapprovedfor chronic obesity management in Canada in 2018, at a totaldailydoseof32mgnaltrexoneand360mgbupropion.Bupropi-on inducessatietycentrallybyenhancingproductionandreleaseofα-melanocyte stimulating hormone (α-MSH) andβ-endorphin fromthepro-opiomelanocortincellsinthearcuatenucleusofthehypothalamus. Naltrexone disrupts the auto-inhibitory effect ofβ-endorphin on the pro-opiomelanocortin cells by blocking theμ-opioid receptors.Naltrexone/bupropionalso influences theme-solimbicrewardsystemtoreducecravings.27Thissynergisticmodeofactionissupportedbytheevidencethattheuseofbupropionornaltrexonealonedonotleadtoclinicallymeaningfulweightloss.28
Eachtabletofthenaltrexone/bupropioncombinationcontains8mgofnaltrexoneand90mgofbupropion.Therecommendedtitration
scheduleisonetabletdailyforthefirstweek,withanincreasebyonetableteachweekuntilthemaintenancedoseoftwotabletstwicedaily(totaldailydose32mg/360mg)isreached.
Amongpatientswithoverweightorobesitywithoutdiabetes,nal-trexone/bupropion32mg/360mgwith ahypocaloricdiet (500kcal/daydeficit)andexercisewasassociatedwithweightlossof-6.1%versus-1.3%inplacebo.4A≥5%weight losswasseenin48%ofpatients,and≥10%weightlosswasseenin25%ofpatients, comparedwith 16% and 7% in the placebo groups,respectively.4Acombinedanalysisofthreenaltrexone/bupropiontrialsfoundthatearlyimprovementsincravingswerepredictiveofgreaterweightlosssuccess.29
Themostcommonsideeffectsofnaltrexone/bupropion includenausea,constipation,headache,vomiting,insomnia,drymouth,dizzinessanddiarrhea.Mostnauseaeventsoccurduringthedoseescalationperiodandaretransient.
Naltrexone/bupropioniscontraindicated inpatientswithuncon-trolledhypertension(seeothercardiovascularriskfactors,below).Anyopioiduseisanabsolutecontraindicationtotheuseofnal-trexone/bupropion. Opioid therapy should be discontinued forseven to 10 days prior to initiation of naltrexone/bupropion toprevent the precipitation of opioidwithdrawal.30 As bupropionisassociatedwithaslightlyincreasedriskofseizure,naltrexone/bupropion is contraindicated in seizure disorders, anorexia ner-vosa, bulimia or patients undergoing abrupt discontinuation ofalcohol,benzodiazepines,barbituratesorantiepilepticdrugs.Nal-trexone/bupropionshouldbedosedwithcautionwithanydrugsthatlowerseizurethreshold.Monoamineinhibitors(MOAIs)canincreasetheriskofhypertensivereactions,andnaltrexone/bupro-pionshouldthereforenotbeusedwithin14daysoftakingmono-amineinhibitors.Naltrexone/bupropionshouldnotbetakenwithahighfatmeal(≥55%fat),asthissignificantlyincreasessystemicexposuretothemedication.31
There are multiple potential drug interactions with naltrexone/bupropion,whichstemfromtheeffectofbupropionanditsme-tabolitestoinhibitthehepaticCYP2D6enzymesystem.Physiciansandpharmacistsmustbeawareoftheimportanceofevaluatingpotentialdruginteractionspriortoinitiatingnaltrexone/bupropi-on.Amongpatientsalreadyreceivingnaltrexone/bupropion,med-icationsmetabolizedbyCYP2D6shouldbestartedatthe lowerendoftheirrecommendeddosagerangewithcautioustitration(e.g. selective serotonin reuptake inhibitors,betablockers,anti-psychotic agents, type 1C antiarrhythmic agents andmany tri-cyclic antidepressants, e.g. citalopram, metoprolol, risperidone,propafenoneanddesipramine,respectively).32Forpatientsalreadyreceiving these medications, consideration should be given fordose reductionwhen starting naltrexone/bupropion. Bupropionmayresultinreducedefficacyoftamoxifenandshouldthereforenotbeusedincombinationwithit.
BupropionisprimarilymetabolizedbytheCYP2B6enzymesystem.Therefore,naltrexone/bupropiondosingshouldnotexceedonetab-lettwicedailywhenusedwithCYP2B6inhibitors(e.g.ticlopidine,
Canadian Adult Obesity Clinical Practice Guidelines 6
clopidogrel).33Naltrexone/bupropion shouldbeavoided inpatientstakingCYP2B6inducersasthesemayreduceefficacyofnaltrexone/bupropionbyreducingbupropionexposure(e.g.ritonavir,lopinavir,efavirenz,carbamazepine,phenobarbital,phenytoin).32 Central ner-voussystemtoxicitycanoccurwhennaltrexone/bupropion isusedconcomitantlywithdopaminergicdrugs(e.g.levodopa,amantadine).
Efficacy of pharmacotherapy on health parameters
Type 2 diabetes mellitus prevention
T2DM is a common complication of obesity, andprevention ofdiabetes is an important goal in chronic obesity management.PeoplewithprediabetesareathighriskofdevelopingT2DM,withabout25%ofindividualswitheitherimpairedfastingglucoseorimpaired glucose tolerance progressing to T2DM over three tofiveyears.34Amongindividualswithprediabetes,onekilogramofweightlossisassociatedwitha16%relativeriskreductioninthedevelopmentofT2DM.35
Pharmacotherapyforobesitycanbeofbenefittopreventordelaythe development of T2DM.Orlistatwas evaluated for diabetespreventioninatrialof3305patientswithobesityandeithernor-mal (79%) or impaired (21%) glucose tolerance. Patientswererandomized to health behaviour changes plus either orlistat orplacebo.10Afterfouryearsoftreatment,thecumulativeincidenceofdiabeteswas6.2%intheorlistatgroupcomparedwith9.0%inplacebo,withacorresponding37.3%decreaseinriskofpro-gressiontoT2DM.PeoplewithimpairedglucosetolerancederivedthegreatestbenefitintermsofdecreasedrateofprogressiontoT2DM, compared to study participants with normoglycemia. Asecondary analysis demonstrated greaterweight loss to be theprimaryreasonfordiabetesprevention.10
Liraglutide3.0mghasdemonstratedefficacytopreventandde-layT2DMamongstpeoplewithprediabetes.TheSCALEObesityandPrediabetestrialrandomized2254patientstoreceiveliraglu-tide3.0mg(n=1505)orplacebo(n=749), inadditiontohealthbehaviourchange.ThetimetoonsetofT2DMoverathree-yeartreatmentperiodinthisstudywas2.7timeslongerwithliraglu-tide3.0mgvs.healthbehaviouralone,andtheriskofdevelopingT2DMwasreducedby79%.2Theseimprovementsarelikelyduetoacombinedeffectoftheantihyperglycemiceffectsofliraglu-tideaswellasliraglutide-mediatedweightloss.
Currently,therearenopublishedstudiesevaluatingtheefficacyofnaltrexone/bupropionondiabetesprevention.
Oursystematicreviewidentifiedonerandomizedcontroltrialeval-uatingtheefficacyofexenatide(ashortactingGLP-1analog)ver-susplaceboonbodyweightandglucosetoleranceamongpeoplewithobesitywithnormoglycemia,impairedglucosetoleranceorimpairedfastingglucose,onabackgroundofhealthbehaviourin-terventionovera24weekperiod.29Theexenatidegroupdemon-strateda-5.1kgweightlosscomparedwith-1.6kgonplacebo.
Impairedfastingtolerancenormalizedin77%ofexenatidetreat-edpatientscomparedwith56%intheplacebogroup.Exenatideisnotindicatedforobesitymanagement,norforthepreventionofT2DM.
Type 2 diabetes mellitus
ObesityinT2DMisassociatedwithpoorerglycemiccontrol,bloodpressureandlipidprofiles,andincreaseduseoflipidloweringandantihypertensivedrugs,comparedwithpeoplewithdiabeteswhodonothaveobesity.36
Theeffectofantidiabeticpharmacotherapyonweightshouldbeconsidered in choosing the most appropriate medication(s) forglycemic control. GLP1 receptor agonists and sodium/glucosecotransporter2 inhibitorsareassociatedwithweight loss inad-ditiontoimprovingglycemiccontrol.Metformin,dipeptidylpep-tidase-4 inhibitorsandacarboseare typicallyweightneutral. In-sulin,insulinsecretagoguesandthiazolidinedionesareassociatedwithweightgain.37Pharmacotherapyforobesitycanbeofbenefitforweightlossandimproveddiabetescontrol.
Orlistathasbeendemonstratedtoimproveglycemiccontrolinpa-tientswithT2DM.Ameta-analysiscomprising2550patientswithT2DMandobesity randomized toorlistat120mgtidorplacebofound thatpatients treatedwithorlistathad significantlygreatermeandecreases in fastingplasmaglucoseandHbA1ccomparedwithplacebo(1.39mmol/lvs.0.47mmol/land0.74%vs.0.31%,respectively).9Weight loss intheorlistatgroupwas-3.8kgcom-paredto-1.4kgonplacebo.Theprimaryreasonforimprovementinglycemiccontrolwithorlistatisweightloss,althoughorlistatmayprovidebeneficialmetaboliceffectsindependentofweightloss.Forpatientswithminimalweightloss(1%ofbaselinebodyweight),or-listatprovidedasignificantlygreaterdecreaseinfastingplasmaglu-cose(0.83mmol/lvs.0.02mmol/l)andHbA1c(0.29%vs.0.14%).9
IntheSCALEdiabetestrial,liraglutide3.0mgwascomparedtolira-glutide1.8mgandplacebo,inadditiontohealthbehaviourchang-es,inpeoplewithobesityandT2DMmanagedwithoralagentsorhealthbehavioursalone.Atoneyear, liraglutide3.0mgreducedweightby -6.0% (n=423) compared to -4.7%on liraglutide1.8mg(n=211)and-2.0%onplacebo(n=212).Aclinicallysignificantweight lossof≥5%wasachievedby54.3%ofpatientson lira-glutide3.0mg,versus40.4%onliraglutide1.8mgand21.4%onplacebo.Weightloss≥10%occurredin25.2%ofpatientsonlira-glutide3.0mgversus15.9%withliraglutide1.8mgversus6.7%ofpeoplereceivinghealthbehaviourmodificationalone.Liraglutide3.0mgreducedHbA1cby1.3%comparedwith1.1%onliraglu-tide1.8mgand0.3%onplacebo.Inaddition,moreparticipantstreatedwithliraglutide3.0mgand1.8mgreducedtheirnetuseoforalantihyperglycemicagentscomparedwithplacebo.7
TheContraveObesityResearchDiabetes(COR-DM)trialevaluatedthesafetyandefficacyofnaltrexone/bupropion32mg/360mginadditiontohealthbehaviourchangesamongstadultswithaBMIof27–45kg/m2andT2DMmanagedwithoral agentsordiet.8
Canadian Adult Obesity Clinical Practice Guidelines 7
Naltrexone/bupropiontreatedpatientsachieveda5%weightre-ductioncomparedwith1.8%intheplacebogroup.Additional-ly,44.5%ofpatientsachieved≥5%weightlosscomparedwith18.9% in theplaceboarm,and18.5%ofpatients lost≥10%weightlosscomparedwith5.7%ofpatientsintheplaceboarm.Patientstreatedwithnaltrexone/bupropiondemonstrateda-0.5%greaterimprovementinA1CcomparedtoplaceboandweremorelikelytoachieveanA1C<7%(44.1%inthenaltrexone/bupro-piongroup versus 26.3% in placebo). The change inA1Cwascorrelatedwith thechange inbodyweight inboth studyarms.However,fewerpatientsreceivingnaltrexone/bupropionrequiredan increase indoseor theadditionofanotheroral antidiabeticagentcomparedwithplacebo(22.3%vs.35.2%,respectively).
Other cardiovascular risk factors
Pharmacotherapy-inducedweight loss can be of benefit to im-provecardiovascularriskfactorsinadditiontoglycemiccontrol.
Ameta-analysisdemonstratedthatorlistatproducedamodestim-provementinlipidprofileandsmallreductionsinbloodpressure(seeTable1)20
Liraglutide reduced systolicbloodpressureby -2.8mmHgcom-paredwithplacebo,withmodestimprovementsinlipidparame-ters.Aheartrateincreaseoftwobeatsperminute(BPM)wasnot-edamongstpeoplewithobesityandprediabetesatthreeyears.2
Naltrexone/bupropion is associated with modest improvementsin lipid parameters.4,8,38,39 Naltrexone/bupropion attenuates thebloodpressurereductionassociatedwithweightloss,whichmaybeduetoitsactiontoinhibitreuptakeofnorepinephrine.Naltrex-one/bupropion is contraindicated in patients with uncontrolledhypertension and shouldbeusedwith caution inpatientswithcontrolledhypertension.31
Regulatoryrequirementsforobesitypharmacotherapydonotin-cludeastandardrequirementforcardiovascularoutcometrialstoassess the cardiovascular safety of thesemedications.However,cardiovascular outcome studies may be required by regulatoryagencies,particularlyifthereisanyconcernforpotentialadverseeffectonanycardiovascularriskfactor.Sibutramine,whichisnolongeravailable inCanada,wasstudiedinacardiovascularout-come trial becauseof reported increases in bloodpressure andheart rate. This study found an increased risk of cardiovasculareventsinpeoplewithpreexistingcardiovasculardisease.
Liraglutidehasbeenshowntoreducecardiovasculareventsandmor-talityinpeoplewithT2DM38ata1.2–1.8mgdose.ThesedatahavebeenacceptedassufficientsafetydatabytheUSFoodandDrugAd-ministrationtoreassurethecardiovascularsafetyofliraglutideinpeo-plewithobesitywithoutT2DM,atthetherapeuticdoseof3.0mg.
TheCardiovascularOutcomesStudyofNaltrexoneSR/BupropionSR in Overweight andObese Subjectswith Cardiovascular RiskFactors (LIGHT) studywasacardiovascularoutcometrialunder-taken toassess the cardiovascular safetyofnaltrexone/bupropi-
on.Interimresultswerereleasedafter25%oftheplannednumberofmajoradversecardiovascularevents(MACE)occurred,compromisingtheintegrityofthetrial.Althoughthetrialwasterminatedupontherecommendationoftheleadinvestigator,theresultsofthepreplanned50%interimanalysiswerereleasedanddemonstratedahazardratioforthetimetothefirstmajoradversecardiaceventof0.88(95%CI:0.57–1.34) in favour of naltrexone/bupropion.40 These results couldnotbeusedtoestablishnon-inferiorityduetothecompromiseofthetrial.Anewcardiovascularoutcometrialisinplanningstages.
Therearenocardiovascularoutcometrialsfororlistat.
Todate,norandomizedclinicaltrialofobesitypharmacotherapyhasdemonstratedareductionincardiovasculareventsormortalityamongstpeoplewithoutdiabetes.
Other obesity-related comorbidities
Weight loss can improve health comorbidities associated withobesity, including hepatic steatosis, polycystic ovary syndrome,obstructivesleepapneaandosteoarthritis.
Nonalcoholic steatohepatitis (NASH)
In a small study (n=41), individuals with BMI >27 kg/m2withbiopsy-proven nonalcoholic steatohepatitis were randomized toreceivea1400Kcal/daydietplusvitaminE(800IU)dailywithorwithoutorlistatfor36weeks.Bothgroupshadsimilarlyimprovedliverenzymesandnonalcoholicfattyliverdiseaseactivityscores,andtherewasnosignificantdifferenceinweightlossbetweengroups(-8.3%onorlistatvs.-6.0%onplacebo).Orlistatdidnotenhanceweightlossorimproveliverenzymes,measuresofinsulinresistanceorhistopathology.SubjectswithgreaterweightlosshadimprovedNASHscoresinboththeorlistatandplacebogroups.41
Inasmallstudyof52patients,liraglutidetreatmentatadoseof1.8mgdailyresultedinresolutionofnonalcoholicsteatohepatitisin39%ofpatients comparedwith9%ofpatientsonplacebo.Theseresultsarebasedonliverbiopsiesperformedafter48weeksoftreatmentandmaybetheresultofthecombinationofweightlossandadirectbeneficialhepaticeffect.21
Naltrexone/bupropionhasnotbeenspecificallystudiedinregardtohepaticsteatosis.
Though data is conflicting, some small studies have suggestedthatmetforminmaycauseasmalldecreaseinBMIof-0.5to-1.3kg/m2withanimprovementinaminotransferasesand/orliverhis-tologyinpatientswithnonalcoholicfattyliverdisease.42,43
Polycystic ovary syndrome
Amongwomenwithpolycysticovarysyndrome,liraglutide1.8mghasbeenshowninasmallstudytoinduceplacebosubtractedweight
Canadian Adult Obesity Clinical Practice Guidelines 8
lossof-5.2kgandreducedliverfatcontent,visceralfatandthepres-ence of nonalcoholic fatty liver disease over 26 weeks.22,44 Thesestudiesdidnotevaluatemenstrual frequency, fertilityorhirsutism.Therearenostudiesofsufficientqualityevaluatingorlistatornaltrex-one/bupropioninpatientswithpolycysticovarysyndrome.
Metforminwithhealthbehaviourchangesmaybeassociatedwithasmall reduction inBMI (-0.73kg/m2)and improvedmenstruation inwomenwithpolycysticovary syndromeover sixmonths, comparedwithhealthbehaviouralone,45accordingtoonesystematicreviewandmeta-analysis.However,anothersystematicreviewandmeta-analysisshowednoeffectofmetforminonweightinthispopulation.46
Ina small studycomparingexenatide,metforminand thecom-binationof exenatide andmetformin inwomenwithpolycysticovary syndrome andoverweight,weight loss in both exenatidearmswassuperiortometforminwithweightlossof-6.0kgonthecombinationofexenatideandmetformin,-3.2kgwithexenatidealoneand-1.6kgonmetforminalone.Thecombinationofexen-atideandmetforminwassuperiortoeitherdrugasmonotherapytoimprovemenstrualcyclicityandovulationrate.47
Obstructive sleep apnea
TheonlyobesitypharmacotherapyavailableinCanadawhichhasbeenspecificallystudiedintheobstructivesleepapneapopulationisliraglutide.Amongpatientswithmoderateorsevereobstructivesleepapneawhowereunableorunwilling touseacontinuouspositive airway pressure machine, liraglutide 3.0mg combinedwithhealthbehaviourmodificationsignificantlyreducedthenum-ber of apnea-hypopnea index events by -12.2 events per hour,comparedwitha reductionof -6.1eventsperhourwithhealthbehaviourmodificationalone.23
Osteoarthritis
Theeffectofobesitypharmacotherapyonosteoarthritishasnotbeenadequatelystudied.
Mental health and quality of life
Thechoiceofagentstotreatmentalhealthconcerns(e.g.depres-sion,psychosis)musttakeeffectonweightintoconsideration(seeTheRoleofMentalHealth inObesityManagement. Pharmaco-therapy forbingeeatingdisorderandattentiondeficithyperac-tivitydisordermustalsotakeeffectonweightintoconsideration.
Whiletherelationshipbetweenmentalhealthandobesityiscom-plex,most studies show that successful obesitymanagement isassociated with an improvement in mental health parameters.Weightlossisassociatedwithimprovedqualityoflifeinsome,butnotall,weightlosstrials.Asmostobesitymedicationsareactiveinthebrain,itisimportanttoascertaintheireffectandsafetyonmentalhealthparameters.
Liraglutide 3.0 mg has been shown to improve health-relat-ed quality of life in peoplewith obesity and prediabetes48 and weight-relatedqualityoflife(QoL)inpeoplewithT2DM,7aswellasdemonstratingneuropsychiatricsafety.49
Naltrexone/bupropionhasdemonstratedagreater improvementinweight-relatedQoL compared to placebo. Study participantslosingthemostweightexperiencedthegreatestimprovementinweight-relatedQoLregardlessofwhethertheweightwaslostonnaltrexone/bupropion or placebo, suggesting that the improve-mentinQoLwasrelatedtotheweightlossratherthanthemed-icationitself.50Therehasbeenalong-standingconcernthatan-tidepressantscanrarely,paradoxically,worsendepressionand/orcauseworseningoremergenceofsuicidalideationorbehaviourduring the early phases of treatment. In theplacebo-controlledclinicaltrialswithnaltrexone/bupropionforthetreatmentofobe-sityinadultpatients,nosuicidesorsuicideattemptswerereport-edinstudiesupto56weeksduration. Inthesestudies,suicidalideationwasreportedbythree(0.20%)of1515patientstreatedwithplacebocomparedwithone(0.03%)of3239treatedwithnaltrexone/bupropion. The sameprecautions pertaining to anti-depressants should be considered when treating patients withnaltrexone/bupropion, including screening patients for suicidalbehavioursandideation.
Weightgainisacommonsideeffectofsomeantipsychoticmedi-cations.Asystematicreviewandmeta-analysiswasconductedof12double-blind,randomized,placebo-controlledtrialsof12–24weeks’duration,includingatotalof743patientswithschizophre-niaor schizoaffectivedisorder. The study found thatmetforminwas effective for the management of antipsychotic inducedweightgaininthispopulation,withameanweightlossinadultsof-3.2kgcomparedwithplacebo.Metforminismostimpactfulearlierinthecourseofantipsychotictreatmentorwithinitiationofantipsychoticmedication,withameandifferenceinweightof-5.9kgcomparedwithplacebo,versus -2.1kg inpatientswhohadbeenonantipsychoticmedicationlongertermbeforestartingmetformin.51
Medications with insufficient data for obesity management
Itisrecognizedthatavarietyofunapprovedpharmacotherapeu-ticapproachesaresometimesbeingutilizedintheclinicalsettinginanattempttoassistwithobesitymanagement.Basedonourreviewofthe literature,there is insufficientevidencetosupporttheuseofpharmacotherapiesorhormonal treatmentstrategies(e.g.,testosterone,thyroidhormone)thatarenotdiscussedinthisdocument.
Twoseparaterandomized,placebo-controlledtrialsevaluatedtheefficacyoftopiramateonweightlossamongpatientswithobesityandT2DMover24–40weeks.Thesetrialsdemonstratedclinicallymeaningfulweight lossof4.5%–6.6%and6.5%–9.1% in the96mg/daygroupand192mg/daydoses,respectively,comparedwith weight losses of 1.7%–2.5% in the placebo groups.52,53
Canadian Adult Obesity Clinical Practice Guidelines 9
Whiletopiramateisnotintendedaspharmacotherapyforobesity,itcouldbeconsideredinpatientswhorequiretopiramateforoth-erindications(e.g.anti-seizureormigrainetherapy)forpatientsinwhomweightgainisaclinicallyrelevantconcern.
Asystematic reviewandmeta-analysisevaluating themetaboliceffectsandweight lossoffluoxetine60mgdaily in215adultswith overweight or obesity and T2DMdemonstrated a -4.3 kgweightlosscomparedwithplacebo.Thesepatientsdidnothavedepression.Follow-upwassixtotwelvemonths infourstudies,butonlytwomonthsinthefifthstudyincluded.Fluoxetineshouldnotbeprescribedforweightlossbutcouldbeconsideredinpa-tientswhorequireitforotherindications,suchasdepression,forpatientsinwhomweightgainisaclinicallyrelevantconcern.
ArecentreviewsummarizesmedicationsavailableinCanadathatcauseweightgain,aswellasalternativechoices.54
Emerging treatments and future directions
TherearemedicationsapprovedforobesitymanagementinothercountriesthatarenotcurrentlyavailableinCanada.Therearealsoseveralagentsunderdevelopmentthatmayprovetobebeneficialforthetreatmentofobesity.
Lorcaserin is a5HT2c receptoragonist that is available in somecountries. It works by stimulation of the pro-opiomelanocortin(POMC)/CART neurons (see The Science of Obesity chapter) toinducesatietyandprovidesa -3.0%placebosubtractedweightlossatadoseof10mgBIDforoneyear.55Lorcaserinhasdemon-stratedcardiovascularsafetyintheCardiovascularSafetyofLorca-serininOverweightorObesePatientscardiovascularoutcometrial(CAMELLIA)butdidnotreducetheriskofcardiovascularevents.56
Phentermineandtopiramate(controlledrelease)areapprovedascombinationtherapyforobesityinsomecountries.PhentermineisanappetitesuppressantthatworksbyinhibitingtheneuropeptideY/agouti-relatedpeptideneuronsandincreasingenergyexpendi-ture.Themechanismbywhichtopiramateinducesweightlossisunclearandmayinvolvemultiplepathways.Atoneyear,-6.6%placebo subtractedweight losswas seenon the lowerdoseof7.5mg/46mg,and-8.6%onthehigherdoseof15mg/92mg.57
Emerging obesity pharmacotherapy
Semaglutide,whichisapprovedfortreatmentofT2DMinCanada,iscurrentlyunderevaluationinclinicaltrialsasapotentialpharmaco-therapeuticagentforchronicobesitymanagement.IntheSemaglu-tideandCardiovascularOutcomesinPatientswithType2Diabetes(SUSTAIN)clinicaltrialprogram,weightlossinpeoplewithT2DMonsemaglutide1.0mgSCweeklyover30–56weeksrangedfrom-4.5to-6.5kg,withupto-5.0kgplacebosubtractedweightloss.58Upto65.7%ofparticipantsinbothsemaglutidedosegroups(0.5mgand1.0mgweekly)achievedweightlossresponsesof≥5%,comparedwithup to11.3%ofpatientsonplacebo.Among patientswith
T2DMwithestablishedcardiovasculardiseaseorathighcardio-vascularrisk,semaglutide0.5mgand1mgweeklywasassoci-atedwith-2.9kgand-4.3kgplacebosubtractedweightlossattwo years, respectively.59 Semaglutide also decreased cardiovas-culareventsamongpatientswithT2DMaged50orgreaterwithestablishedcardiovasculardiseaseorathighriskofcardiovasculardiseasecomparedwithplacebo(heartrate,0.74(95%CI,0.58–0.95)overtwoyears.59Amongpeoplewithobesitywithoutdiabe-tes,semaglutideatadoseofupto0.4mgsubcutaneousperdaydemonstratedweightlossofupto-13.8%comparedwith-2.3%on placebo.60 A cardiovascular outcome trial of semaglutide inpeoplewithobesitywithoutdiabetesbutwithapriorhistoryofcardiovasculareventsiscurrentlyunderway.
Multipletreatmentoptionsarebeingstudied,whichincludemono-therapy or combinations of various hormones (e.g. GLP-1, GIP,glucagon,oxyntomodulin,amylin,PYY3-36). It isanticipatedthatadministering combinationsof thesehormoneswill bebeneficialtoaddressthehighlyredundanthormonalphysiologythatdefendsbodyweight.
Canadian Adult Obesity Clinical Practice Guidelines 10
Figure 1. Algorithm: Choice of Obesity Pharmacotherapy
BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2
plus obesity-related co-morbidities
Consider co-morbidities or specific features
Assess after 3 months on therapeutic dose
Diabetes, prediabetes, hypertension, obstructive
sleep apnea, polycystic ovary syndrome
Liraglutide 1st choice (for DM level 1, grade A;
preDM level 2, grade B)
Naltrexone/bupropion 2nd (for DM level 2, grade B)
Orlistat 3rd (for DM level 2, grade B)
Not sufficiently successful for weight management
Discontinue medication and try second line OR
continue medication and add second-line agent
Craving, depression, smoking
Naltrexone/bupropion 1st choice
Liraglutide 2nd
Orlistat 3rd
Successful for weight management
Continue medication
Consider stopping or changing meds associated
with weight gain if possible
Canadian Adult Obesity Clinical Practice Guidelines 11
Correspondence:[email protected]
References
1. Pi-SunyerX,AstrupA,FujiokaK,etal.ARandomized,ControlledTrialof3.0mgofLiraglutideinWeightManagement.NEnglJMed.2015;373(1):11-22.doi:10.1056/NEJMoa1411892
2. RouxCW,AstrupA,FujiokaK,etal.3yearsofliraglutideversusplacebofortype 2 diabetes risk reduction and weight management in individuals withprediabetes:arandomised,double-blindtrial.Lancet.2017;389(10077):1399-1409.doi:10.1016/S0140-6736(17)30069-7
3. Wadden TA,Hollander P, Klein S, et al.Weightmaintenance and additionalweight loss with liraglutide after low-calorie-diet-induced weight loss: TheSCALEMaintenance randomized study. Int J Obes. 2013;37(11):1443-1451.doi:10.1038/ijo.2013.120
4. Greenway FL, FujiokaK, Plodkowski RA, et al. Effect of naltrexoneplus bu-propion on weight loss in overweight and obese adults ( COR-I ): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet.2010;376(9741):595-605.doi:10.1016/S0140-6736(10)60888-4
5. Rucker D, Padwal R, Li SK, Curioni C, Lau DCW, Janeiro R De. Long termpharmacotherapy for obesity and overweight: updatedmeta-analysis. BMJ.2007;335(7631):1194-1199.doi:10.1136/bmj.39385.413113.25
6. RichelsenB,TonstadS,RossnerS,etal.EffectofOrlistatonWeightRegainandCardiovascularRiskFactorsFollowingaVery-Low-EnergyDiet inAbdominallyObesePatients:a3-yearrandomized,placebo-controlledstudy.DiabetesCare.2007;30(1):27-32.doi:10.2337/dc06-0210
7. DaviesMJ,BergenstalR,BodeB,etal.EfficacyofLiraglutideforWeightLossAmongPatientsWithType2DiabetesTheSCALEDiabetesRandomizedClinicalTrial.JAMA.2015;314(7):687-699.doi:10.1001/jama.2015.9676
8. HollanderP,GuptaA,PlodkowskiR,etal.Effectsofnaltrexonesustained-re-lease/bupropion sustained-release combination therapy on bodyweight andglycemicparameters inoverweightandobesepatientswith type2diabetes.DiabetesCare.2013;36(12):4022-4029.doi:10.2337/dc13-0234
9. JacobS,RabbiaM,MeierMK,HauptmanJ.Orlistat120mgimprovesglycaemiccontrolintype2diabeticpatientswithorwithoutconcurrentweightloss.Diabe-tesObesMetab.2009;11(4):361-371.doi:10.1111/j.1463-1326.2008.00970.x
10. TorgersonJ,HauptmanJ,BoldrinM,SjöströmL.XENicalinthepreventionofdiabetesinobesesubjects(XENDOS)study:arandomizedstudyoforlistatasanadjuncttolifestylechangesforthepreventionoftype2diabetesinobesepatients.DiabetesCare.2004;27(1):155-161.
11. KnowlerWC,Barrett-ConnorE, FowlerSE, et al.Reduction in the incidenceof type 2 diabetes with lifestyle intervention or metformin. N Engl J Med.2002;346(6):393-403.doi:10.1056/NEJMoa012512
12. PromratK,KleinerDE,NiemeierHM,etal.RandomizedControlledTrialTest-ing the Effects ofWeight Loss onNonalcoholic Steatohepatitis. Hepatology.2010;51(1):121-129.doi:10.1002/hep.23276
13. StevensVJ,CorriganSA,ObarzanekE,etal.WeightLossInterventioninPhase1oftheTrialsofHypertensionPrevention.ArchInternMed.1993;153(7):849-858.
14. JamesWPT,AstrupA,FinerN,etal.Effectofsibutramineonweightmaintenanceafterweightloss:arandomisedtrial.STORMStudyGroup.SibutramineTrialofObesityReductionandMaintenance.Lancet.2000;356(9248):2119-2125.
15. McneelyW,BenfieldP.Orlistat.1998;56(2):241-249.
16. Roche.XenicalProductMonograph.Retrievedfromwww.rochecanada.com.
17. PadwalR,KezouhA,LevineM,EtminanM.Long-termpersistencewithorlistatandsibutramineinapopulation-basedcohort.IntJObes.2007;31(10):1567-1570.doi:10.1038/sj.ijo.0803631
18. WeirMA,BeyeaMM,GomesT,etal.Orlistatandacutekidneyinjury:Ananal-ysis of 953 Patients. Arch Intern Med. 2011;171(7):703-704. doi:10.1001/archinternmed.2011.103
19. WilsonN,ShahN,ManitpisitkulW,etal.LiverFailureRequiringTransplantationAfterOrl-istatUse.AmCollClinPharm.2011;31(11):1145-1145.doi:10.1592/phco.31.11.1145
20. ZhouY,MaX,WuC,etal.EffectofAnti-ObesityDrugonCardiovascularRiskFactors: A Systematic Review andMeta-Analysis of Randomized ControlledTrials.PLoSOne.2012;7(6):e39062.doi:10.1371/journal.pone.0039062
21. ArmstrongMJ,GauntP,AithalGP,etal.Liraglutidesafetyandefficacyinpa-tientswithnon-alcoholicsteatohepatitis(LEAN):amulticentre,double-blind,randomised,placebo-controlledphase2study.Lancet.2016;387(10019):679-690.doi:10.1016/S0140-6736(15)00803-X
22. NylanderM,FrøssingS,KistorpC,FaberJ,SkoubySO.Liraglutideinpolycysticovarysyndrome:arandomizedtrial,investigatingeffectsonthrombogenicpo-tential.EndocrConnect.2017;6(2):89-99.doi:10.1530/ec-16-0113
23. BlackmanA,FosterGD,ZammitG,etal.Effectofliraglutide3.0mginindivid-ualswithobesityandmoderateorsevereobstructivesleepapnea:theSCALESleep Apnea randomized clinical trial. Int J Obes. 2016;40(8):1310-1319.doi:10.1038/ijo.2016.52
24. SecherA,JelsingJ,BaqueroAF,etal.ThearcuatenucleusmediatesGLP-1recep-toragonistliraglutide-dependentweightloss.JClinInvest.2014;124(10):4473-4488.doi:10.1172/JCI75276.balance
25. JelsingJ,VrangN,HansenG,RaunK,KnudsenLB.Liraglutide:short-livedef-fectongastricemptying—longlastingeffectsonbodyweight.Diabetes,ObesMetab.2012;14(6):1-8.
26. Novo-Nordisk. Product Monograph SAXENDA. https://www.novonordisk.ca/content/dam/Canada/AFFILIATE/www-novonordisk-ca/OurProducts/PDF/Saxen-da_PM_English.pdf.2017.
27. Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational Design of aCombinationMedication for the Treatment of Obesity. Obes (Silver Spring).2009;17(1):30-39.doi:10.1038/oby.2008.461
28. SmithS,FujiokaK,GuptaA,etal.Combinationtherapywithnaltrexoneandbupropionforobesityreducestotalandvisceraladiposity.Diabetes,ObesMe-tab.2013;15(9):863-866.
Downloadedfrom:https://obesitycanada.ca/guidelines/pharmacotherapy
ThisworkislicensedunderaCreativeCommonsAttribution-NonCommercial-NoDerivatives4.0InternationalLicense(CCBY-NC-ND4.0)
ThesummaryoftheCanadianAdultObesityClinicalPracticeGuidelineispublishedintheCanadianMedicalAssociationJournal,andcontainsinformationonthefullmethodology, managementofauthors’competinginterests,abriefoverviewofallrecommendationsandotherdetails.MoredetailedguidelinechaptersarepublishedontheObesityCanadawebsiteatwww.obesitycanada.ca/guidelines.
Canadian Adult Obesity Clinical Practice Guidelines 12
29. RosenstockJ,KlaffL,SchwartsS,etal.Effectsofexenatideandlifestylemodifi-cationonbodyweightandglucosetoleranceinobesesubjectswithandwithoutpre-diabetes.DiabetesCare.2010;33(6):1173-1175.doi:10.2337/dc09-1203.
30. Takeda Pharmaceuticals America I. Highlights of Prescribing Informa-tion. Retrieved from https//www.accessdata.fda.gov/drugsatfda_docs/la-bel/2014/200063s000lbl.pdf.2014.
31. Valeant.ProductMonograph-Contrave.Retrievedfromhttps//pdf.hres.ca/dpd_pm/00043849PDF.2018.
32. BjornssonTD,CallaghanJT,EinolfHJ,etal.TheConductofInVitroandInVivoDrug-DrugInteractionStudies:APhRMAPerspective.JofClinicalPharmacol.2003;43(5):443-469.doi:10.1177/0091270003252519
33. TurpeinenM,TolonenA,UusitaloJ,JalonenJ,PelkonenO,LaineK.EffectofclopidogrelandticlopidineoncytochromeP4502B6activityasmeasuredbybupropionhydroxylation.2005;77(6):553-559.doi:10.1016/j.clpt.2005.02.010
34. NathanD,DavidsonM,DeFronzoR,etal. ImpairedFastingGlucoseand Im-pairedGlucoseTolerance.2007;30(3):753-759.doi:10.2337/dc07-9920
35. KnowlerW,FowlerS,HammanR,etal.10-yearfollow-upofdiabetesincidenceandweightlossintheDiabetesPreventionProgramOutcomesStudy.Lancet.2009;374(9702):1677-1686.doi:10.1016/S0140-6736(09)61457-4.10-year
36. DaousiC,Casson I,GillG,MacFarlane I,Wilding J,Pinkney J.Prevalenceofobesityintype2diabetesinsecondarycare:associationwithcardiovascularriskfactors.PostgrMedJ.2006;82(966):280-284.doi:10.1136/pmj.2005.039032
37. LipscombeL,BoothG,ButaliaS,etal.PharmacologicGlycemicManagementofType2DiabetesinAdultsDiabetesCanadaClinicalPracticeGuidelinesExpertCommittee.CanJDiabetes.2018;42:S88-S108.
38. MarsoS,DanielsG,Brown-FrandsenK,KristensenP.LiraglutideandCardio-vascularOutcomes inType2Diabetes.NEngl JMed.2016;375(4):311-322.doi:10.1002/oby.20309
39. WaddenTA,ForeytJP,FosterGD,etal.WeightLossWithNaltrexoneSR/Bu-propion SR Combination Therapy as an Adjunct to Behavior Modification:TheCOR-BMODTrial.Obes (SilverSpring.2011;19(1):110-120.doi:10.1038/oby.2010.147
40. NissenSE,WolskiKE,PrcelaL,etal.EffectofNaltrexone-BupropiononMajorAdverseCardiovascularEventsinOverweightandObesePatientsWithCardio-vascular Risk Factors A RandomizedClinical Trial. JAMA. 2016;315(10):990-1004.doi:10.1001/jama.2016.1558
41. Harrison SA, Fecht W, Brunt EM, Neuschwander-tetri BA. Orlistat for over-weightsubjectswithnonalcoholicsteatohepatitis:Arandomized,prospectivetrial.Hepatology.2009;49(01):80-86.doi:10.1002/hep.22575
42. Bugianesi E, Gentilcore E, Manini R, et al. A randomized controlled trialofmetformin versus vitamin E or prescriptive diet in nonalcoholic fatty liverdisease. Am J Gastroenterol. 2005;100(5):1082-1090. doi:10.1111/j.1572-0241.2005.41583.x
43. YgunAU,AdayifciAK, IsikAT,etal.Metformin in thetreatmentofpatientswithnon-alcoholic steatohepatitis.Aliment Pharmacol Ther. 2004;19(5):537-544.doi:10.1111/j.1365-2036.2004.01888.x
44. FrøssingS,NylanderM,ChabanovaE,etal.Effectofliraglutideonectopicfatinpolycysticovarysyndrome:Arandomizedclinicaltrial.DiabetesObesMetab.2018;20(1):215-218.doi:10.1111/dom.13053
45. NaderpoorN,ShorakaeS,CourtenBDe,MissoML,MoranLJ,TeedeHJ.Met-forminandlifestylemodificationinpolycysticovarysyndrome:systematicre-viewandmeta-analysis.HumReprodUpdat.2015;21(5):560-574.doi:10.1093/humupd/dmv025
46. WangF,WuY,ZhuY,etal.Pharmacologic therapy to induceweight loss inwomenwhohaveobesity/overweightwithpolycysticovarysyndrome:asys-tematicreviewandnetworkmeta-analysis.ObesRev.2018;19(10):1424-1445.doi:10.1111/obr.12720
47. Elkind-hirschK,MarrioneauxO,BhushanM,VernorD,BhushanR.Comparisonof Single andCombinedTreatmentwith Exenatide andMetforminonMen-strualCyclicity inOverweightWomenwithPolycysticOvarySyndrome.JClinEndocrinolMetab.2008;93(7):2670-2678.doi:10.1210/jc.2008-0115
48. Kolotkin R, SmolarzG,MeinckeH, FujiokaK. Improvements in health-relat-ed quality of life over 3 yearswith liraglutide 3. 0mg comparedwith pla-cebo in participants with overweight or obesity. Clin Obes. 2018;8(1):1-10.doi:10.1111/cob.12226
49. O’NeilPMO,ArodaVR,AstrupA,etal.Neuropsychiatricsafetywithliraglutide3.0mgforweightmanagement:Resultsfromrandomizedcontrolledphase2and3atrials.Diabetes,ObesMetab.2017;19(11):1529-1536.doi:10.1111/dom.12963
50. KolotkinRL,ChenS,KlassenP,GilderK,GreenwayFL.Patient-reportedquali-tyoflifeinarandomizedplacebo-controlledtrialofnaltrexone/bupropionforobesity.ClinObesity,.2015;5(5):237-244.doi:10.1111/cob.12108
51. SilvaVADe,SuraweeraC,RatnatungaSS,DayabandaraM.Metformininpre-ventionandtreatmentofantipsychoticinducedweightgain:asystematicre-viewandmeta-analysis.BMCPsychiatry.2016;16(1):341.doi:10.1186/s12888-016-1049-5
52. Toplak H, Hamann A, Moore R, et al. Efficacy and safety of topiramate incombinationwithmetformin in the treatmentofobesesubjectswith type2diabetes: a randomized, double-blind, placebo-controlled study. Int J Obes.2007;31(1):138-146.doi:10.1038/sj.ijo.0803382
53. StenlofK,RossnerS,VercruyssEF,KumarA,FitchetM,SjostromL.Topiramateinthetreatmentofobesesubjectswithdrug-naivetype2diabetes.DiabetesObesMetab.2007;9(3):360-368.doi:10.1111/j.1463-1326.2006.00618.x
54. Wharton S, Raiber L, Serodio KJ, Lee J, Christensen RAG.Medications thatcauseweight gain and alternatives in Canada: a narrative review. DiabetesMetabSyndrObes.2018;21:427-438.
55. FidlerMC,SanchezM,RaetherB,etal.AOne-YearRandomizedTrialofLorca-serinforWeightLossinObeseandOverweightAdults:TheBLOSSOMtrial.JClinEndocrinolMetab.2011;96(10):3067-3077.doi:10.1210/jc.2011-1256
56. BohulaE,WiviottS,McGuireD,InzucchiS,KuderJ.CardiovascularSafetyofLorcaserininOverweightorObesePatients.NEnglJMed.2018;379(12):1107-1118.doi:10.1056/NEJMoa1808721
57. GaddeKM,AllisonDB,RyanDH,etal.Effectsoflow-dose,controlled-release,phentermineplustopiramatecombinationonweightandassociatedcomorbid-itiesinoverweightandobeseadults(CONQUER):Arandomised,placebo-con-trolled,phase3trial.Lancet.2011;377(9774):1341-1352.doi:10.1016/S0140-6736(11)60205-5
58. GoldenbergRM,SteenO.Semaglutide:ReviewandPlaceinTherapyforAdultsWith Type 2 Diabetes. Can J Diabetes. 2019;43(2):136-145. doi:10.1016/j.jcjd.2018.05.008
59. MarsoS,BainS,ConsoliA,etal.SemaglutideandCardiovascularOutcomesin Patients with Type 2 Diabetes. Engl J Med. 2016;375(19):1834-1844.doi:10.1056/NEJMoa1607141
60. O’NeilPM,BirkenfeldAL,McGowanB,etal.Efficacyandsafetyofsemaglu-tide comparedwith liraglutide and placebo forweight loss in patientswithobesity:arandomised,double-blind,placeboandactivecontrolled,dose-rang-ing, phase 2 trial. Lancet. 2018;392(10148):637-649. doi:10.1016/S0140-6736(18)31773-2
61. Domecq JP, Prutsky G, Leppin A, et al. Drugs Commonly Associated WithWeightChange:ASystematicReviewandMeta-analysis.JClinEndocrinolMe-tab.2015;100(2):363-370.doi:10.1210/jc.2014-3421